Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges: 2022-2025

Historic Amortization of Deferred Charges for Madrigal Pharmaceuticals (MDGL) over the last 4 years, with Sep 2025 value amounting to $329,000.

  • Madrigal Pharmaceuticals' Amortization of Deferred Charges fell 31.46% to $329,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 31.44%. This contributed to the annual value of $2.1 million for FY2024, which is 13.46% down from last year.
  • Madrigal Pharmaceuticals' Amortization of Deferred Charges amounted to $329,000 in Q3 2025, which was down 11.32% from $371,000 recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $753,000 during Q4 2023, with a 5-year trough of $178,000 in Q2 2022.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Amortization of Deferred Charges value was $480,000 (recorded in 2024), while the average stood at $512,636.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Amortization of Deferred Charges spiked by 211.24% in 2023, and later plummeted by 35.99% in 2024.
  • Over the past 4 years, Madrigal Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $306,000 in 2022, then surged by 146.08% to $753,000 in 2023, then crashed by 35.99% to $482,000 in 2024, then plummeted by 31.46% to $329,000 in 2025.
  • Its Amortization of Deferred Charges was $329,000 in Q3 2025, compared to $371,000 in Q2 2025 and $436,000 in Q1 2025.